3-methylamino-1,2,4-triazolo<4,3-a>pyridine | 76273-33-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 三唑并吡啶类
• 英文名称: 3-methylamino-1,2,4-triazolo<4,3-a>pyridine
• 英文别名: N-methyl-[1,2,4]triazolo[4,3-a]pyridin-3-amine；3-Methylamino-s-triazolo<4,3-a>pyridin；methyl-[1,2,4]triazolo[4,3-a]pyridin-3-yl-amine
• CAS: 76273-33-1
• 化学式: C₇H₈N₄
• mdl: MFCD09834907
• 分子量: 148.167
• InChiKey: KAKHWQPJTJRXQT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.142
• 拓扑面积：
  42.2
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2933990090

反应信息

• 作为产物：
  描述：

  1-(2-pyridyl)-4-methylthiosemicarbazide 在 碘 、 potassium carbonate 作用下， 以 1,4-二氧六环 为溶剂， 反应 4.0h， 以70 mg的产率得到3-methylamino-1,2,4-triazolo<4,3-a>pyridine
  参考文献：
  名称：

  通过向异硫氰酸酯依次添加芳基肼和I 2介导的环脱硫反应，合成熔融的3-氨基-1,2,4-三唑

  摘要：

  通过将芳基肼加到异硫氰酸酯中，然后进行I 2介导的氧化环脱硫，合成了多种稠合的3-氨基-1,2,4-三唑衍生物。这种无过渡金属的合成方法可轻松，高效地从容易获得的底物中轻松获得1,2,4-三唑并[4,3- a ]吡啶和带有3-氨基取代基的相关杂环骨架。

  DOI：

  10.1016/j.tet.2018.05.009

文献信息

• Ogura, Haruo; Mineo, Satoshi; Nakagawa, Kunio, Heterocycles, 1980, vol. 14, # 8, p. 1125 - 1126
  作者：Ogura, Haruo、Mineo, Satoshi、Nakagawa, Kunio

  DOI：——

  日期：——
• USE OF SUBSTITUTED OXADIAZOLES FOR COMBATING PHYTOPATHOGENIC FUNGI
  申请人：BASF SE

  公开号：EP3151669B1

  公开（公告）日：2020-10-28
• EP3756464A1
  申请人：——

  公开号：EP3756464A1

  公开（公告）日：2020-12-30
• HETEROCYCLIC COMPOUNDS THAT INHIBIT THE KINASE ACTIVITY OF MNK USEFUL FOR TREATING VARIOUS CANCERS
  申请人：eFFECTOR Therapeutics, Inc.

  公开号：US20170145009A1

  公开（公告）日：2017-05-25

  The present invention provides synthesis, pharmaceutically acceptable formulations and uses of compounds in accordance with Formula IA or Formula IB, as well as stereoisomers, tautomers or pharmaceutically acceptable salts thereof. For Formula IA and Formula IB compounds A 1 , A 2 , A 3 , A 4 , W 1 , W 2 , Y, X, R 1 , R 2 , R 3 , R 4a , R 4b , R 5a , R 5b , R 6 , R 7 , R 8 , R 9 , R 9a , R 9b , R 10 and subscript n are as defined in the specification. The inventive Formula IA and Formula IB compounds are inhibitors of Mnk and find utility in any number of therapeutic applications, including but not limited to treatment of inflammation and various cancers.
• [EN] MONOACYLGLYCEROL LIPASE MODULATORS<br/>[FR] MODULATEURS DE LA MONOACYLGLYCÉROL LIPASE
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2020065613A1

  公开（公告）日：2020-04-02

  Fused compounds of Formula (I) and Formula (II), pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions associated with MGL modulation, such as those associated with pain, psychiatric disorders, neurological disorders (including, but not limited to major depressive disorder, treatment resistant depression, anxious depression, bipolar disorder), cancers and eye conditions. and; Wherein R1, R2, R2a, R3, R3a, R4, and R4a are defined herein.